Welcome to our dedicated page for IGM Biosciences news (Ticker: IGMS), a resource for investors and traders seeking the latest updates and insights on IGM Biosciences stock.
IGM Biosciences, Inc. (Nasdaq: IGMS) is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for cancer, infectious diseases, and autoimmune and inflammatory diseases. At the core of the company’s innovation is its proprietary IgM antibody technology platform, which is optimized for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines.
IGM Biosciences’ leading product candidate is IGM-2323, a bispecific IgM antibody currently in Phase 1 clinical trials aiming to treat patients with B cell non-Hodgkin lymphoma (NHL) and other B cell malignancies. Another promising candidate, IGM-8444, targets death receptor 5 (DR5) proteins and is being developed for the treatment of colorectal cancer. The company is also advancing IGM-7354, a bispecific IgM antibody designed to deliver interleukin-15 cytokines to PD-L1 expressing cells in patients with solid and hematologic malignancies.
IGM Biosciences has formed strategic collaborations to enhance its research and development efforts. These include partnerships with Atreca Inc. and BeiGene Ltd. to identify and develop novel IgM and IgA antibodies against SARS-CoV-2, and a strategic research collaboration with AbCellera to discover IgM antibodies. Additionally, IGM has an exclusive worldwide collaboration agreement with Sanofi to develop and commercialize IgM antibody agonists targeting oncology, immunology, and inflammation.
The financial outlook for IGM remains robust. For the 2023 fiscal year, the company projected operating expenses between $275 million and $285 million, including a non-cash stock-based compensation expense of around $50 million. IGM expects to end 2023 with over $325 million in cash and investments, ensuring its operations are funded into the second half of 2025.
Recent updates highlight significant progress in IGM’s pipeline. Notably, the company continues to advance candidates such as Imvotamab for severe systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
IGM’s commitment to innovation is demonstrated by its ongoing efforts to develop novel therapies that meet unmet medical needs. With a robust pipeline and strategic partnerships, IGM Biosciences aims to make significant strides in the biopharmaceutical industry.
IGM Biosciences (Nasdaq: IGMS) announced its fourth quarter and full year 2022 financial results will be reported on March 30, 2023. A live conference call and webcast will follow at 4:30 p.m. ET, where management will discuss financial outcomes and provide corporate updates. The company is focused on developing engineered IgM antibodies to address cancer, infectious diseases, and autoimmune conditions. IGM has a collaboration with Sanofi for IgM antibody development, enhancing its pipeline's potential. Investors can access the webcast via their website's 'Events and Presentations' section.
Medivir AB (Nasdaq Stockholm: MVIR) announced that it will present data on its leading program, fostroxacitabine bralpamide (fostrox), at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023, in Orlando, USA. The presentation, led by CSO Fredrik Öberg, will cover the anti-tumor effects of fostrox combined with an anti-PD1 antibody and a kinase inhibitor. The study suggests that this combination may enhance tumor antigen presentation and immune response, addressing the significant unmet medical need in treating hepatocellular carcinoma (HCC), which accounts for high cancer mortality rates.
Medivir AB (Nasdaq Stockholm: MVIR) announced the initiation of treatment for the first patient with hepatocellular carcinoma (HCC) in the phase 2a trial of fostroxacitabine bralpamide (fostrox) in combination with Lenvima®.
This trial is part of an ongoing multicenter study aimed at patients with HCC who have not responded to or cannot tolerate existing therapies. Preliminary results from the phase 1b study indicate that fostrox has a favorable safety profile. The recommended dose for the combination with Lenvima® has been established at 30 mg, and the study aims to recruit up to 30 patients across clinics in Great Britain, Spain, and South Korea.
Medivir AB (Nasdaq Stockholm: MVIR) will participate in the Stockholm Corporate Finance Life Science Day on March 9, 2023. CEO Jens Lindberg is set to present the company's ongoing clinical study with fostroxacitabine bralpamide (fostrox) at 08:30 CET. The presentation will be accessible on Medivir's website post-event. Medivir focuses on developing innovative cancer treatments addressing significant unmet medical needs, particularly targeting liver cancer cells to minimize side effects. The company collaborates with partners, including IGM Biosciences (Nasdaq: IGMS), for further drug development.
On February 23, 2023, Medivir AB, a pharmaceutical firm focused on cancer treatments, announced its participation in the Erik Penser Bank Healthcare Day. CEO Jens Lindberg will discuss the ongoing clinical study of fostroxacitabine bralpamide (fostrox). The presentation will be accessible on Medivir's website post-event. Medivir aims to address high unmet medical needs in cancer treatment, particularly with fostrox, which targets liver cancer cells while minimizing side effects. Additionally, Medivir collaborates with IGM Biosciences (IGMS) for the development of Birinapant in solid tumor treatments. For more details, visit www.medivir.com.
Medivir AB (MVIR), a pharmaceutical company focused on innovative cancer treatments, announced that Pia Baumann has joined as Chief Medical Officer. She brings extensive oncology experience, previously holding senior roles at AstraZeneca, Takeda, and Incyte. Baumann's expertise will be pivotal as Medivir advances its drug candidate, fostroxacitabine bralpamide (fostrox), into the expansion phase (phase 2a) in combination with Lenvima®. Medivir aims to address high unmet medical needs in cancer therapy, particularly targeting liver cancer cells with minimal side effects.
Medivir AB (Nasdaq Stockholm: MVIR) has successfully completed the initial dose escalation part (phase 1b) of its study on fostroxacitabine bralpamide (fostrox) for hepatocellular carcinoma (HCC) in combination with Lenvima®. Preliminary results indicate a positive safety and tolerability profile, with no dose-limiting toxicity reported. The recommended dose for the phase 2a study has been set at 30 mg. The trial aims to evaluate the efficacy of fostrox in patients unresponsive to first-line treatments. Further recruitment for the phase 2a part will involve up to 30 patients across 14 clinics in the UK, Spain, and South Korea.
MOUNTAIN VIEW, Calif., Feb. 2, 2023 – IGM Biosciences (Nasdaq: IGMS) announced that CEO Fred Schwarzer will participate in a fireside chat at the Guggenheim 2023 Oncology Conference on February 9, 2023, at 1:35 p.m. EST in New York. A live webcast will be available on the Company’s website, and a replay will be archived for 30 days post-event.
IGM Biosciences specializes in engineered IgM antibodies for treating cancer and other diseases. The Company collaborates with Sanofi to develop IgM antibody agonists targeting oncology and immunology. For more details, visit www.igmbio.com.
IGM Biosciences announces the initiation of a Phase 1 clinical trial for IGM-7354, an IL-15/IL-15R IgM antibody targeting solid and hematologic malignancies. The trial aims to assess the safety, pharmacokinetics, and immune cell proliferation in patients with relapsed or refractory solid tumors. If successful, the company may advance to combination studies with T cell engaging antibodies and CAR-T cells as early as 2024. The development represents a significant milestone, focusing on enhancing immune activity in the tumor microenvironment while minimizing systemic toxicity. Collaboration with Sanofi is expected to drive further advancements.
Medivir AB (Nasdaq Stockholm: MVIR) announced its participation in the Redeye Fight Cancer Day on
FAQ
What is the current stock price of IGM Biosciences (IGMS)?
What is the market cap of IGM Biosciences (IGMS)?
What is IGM Biosciences, Inc.?
What are the key product candidates of IGM Biosciences?
What diseases is IGM Biosciences targeting?
Who are IGM Biosciences' strategic partners?
What financial outlook has IGM Biosciences projected for 2023?
What is IGM-2323?
What is the IgM antibody technology platform?
What is the significance of IGM Biosciences' collaboration with Sanofi?
What recent developments have been made in IGM's pipeline?